Gal 475
Alternative Names: Gal-475Latest Information Update: 18 Sep 2023
Price :
$50 *
At a glance
- Originator Neurim Pharmaceuticals
- Class
- Mechanism of Action Chemoreceptor cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Sleep apnoea syndrome
Most Recent Events
- 21 Apr 2023 Phase-I clinical trials in Sleep apnoea syndrome in Israel (PO)